stoxline Quote Chart Rank Option Currency Glossary
Cyclerion Therapeutics, Inc. (CYCN)
2.11  -0.345 (-14.05%)    06-13 16:00
Open: 1.96
High: 2.11
Volume: 1,363
Pre. Close: 2.455
Low: 1.96
Market Cap: 6(M)
Technical analysis
2024-06-13 4:42:36 PM
Short term     
Mid term     
Targets 6-month :  3.14 1-year :  3.67
Resists First :  2.69 Second :  3.15
Pivot price 2.64
Supports First :  1.96 Second :  1.63
MAs MA(5) :  2.36 MA(20) :  2.68
MA(100) :  3 MA(250) :  3.22
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  23.1 D(3) :  20.3
RSI RSI(14): 27.8
52-week High :  5.25 Low :  1.75
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CYCN ] has closed below the lower bollinger band by 6.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CYCN ] is to continue within current trading range. Bollinger Bands are 26% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.12 - 2.13 2.13 - 2.14
Low: 1.93 - 1.94 1.94 - 1.95
Close: 2.09 - 2.11 2.11 - 2.13
Company Description

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Headline News

Mon, 04 Dec 2023
Cyclerion Appoints Regina Graul, Ph.D., as President - citybiz

Mon, 04 Dec 2023
Cyclerion Appoints Regina Graul, Ph.D., as President - Yahoo Finance

Tue, 28 Nov 2023
Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses - Yahoo Finance

Mon, 31 Jul 2023
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets - GlobeNewswire

Mon, 15 May 2023
Cyclerion Announces Reverse Stock Split - Yahoo Finance

Fri, 12 May 2023
Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 3 (M)
Shares Float 1 (M)
Held by Insiders 21.8 (%)
Held by Institutions 41.3 (%)
Shares Short 19 (K)
Shares Short P.Month 20 (K)
Stock Financials
EPS -4.56
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.97
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -43.8 %
Return on Equity (ttm) -158.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -17 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -0.47
PEG Ratio 0
Price to Book value 0.53
Price to Sales 0
Price to Cash Flow -0.32
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android